Detection of TT virus DNA in specimens other than blood

Roß, R. Stefan; Viazov, Sergei; Runde, Volker; Schaefer, UW; Roggendorf, Michael

doi:10.1016/s1386-6532(99)00015-3

Cited by 92 publications

(70 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The qualitative and quantitative PCR analysis showed the presence of TTV in feces [11,[84][85][86], in fresh water and waste water [87,88], in saliva and throat swabs [85,89,90], in semen and cervical swabs [91][92][93], in amniotic fluids, cord cells [94][95][96] and Breast Milk [97][98][99] so the other probable modes of spread may be oral fecal, water borne, respiratory tract, sexual transmission and Mother-Child transmission respectively.…”

Section: Modes Of Transmission Of Ttvmentioning

confidence: 99%

Current and Future Prospects of Torque Teno Virus

Elsaie¹

2013

J Vaccines Vaccin

View full text Add to dashboard Cite

Human health has a significant importance and it is directly affected by a number of factors like different diseases including microbial and viral infections. Up till now we have paid attention to the disease causing viruses and pathogens and less has been investigated about the usefulness of normal viral flora. One such orphan virus is Torque Teno Virus (TTV). The virus is present in healthy as well as diseased population, indicating its high prevalence. The virus is ubiquitous to human body as it is present in almost all tissues and organs and this is the property that can be utilized for targeted drug delivery. Another potentially useful property of this virus is TTV derived Apoptosis Inducing protein that can be a hope for the affectees.

show abstract

Section: Modes Of Transmission Of Ttvmentioning

confidence: 99%

Current and Future Prospects of Torque Teno Virus

Elsaie¹

2013

J Vaccines Vaccin

View full text Add to dashboard Cite

show abstract

“…To date, there are relatively few published studies of BCRP gene expression in clinical samples. BCRP seems to be expressed at low levels in breast cancer cells as well as leukemic cells (Ross et al, 2000;Kanzaki et al, 2001). Furthermore, the expression of BCRP in breast carcinoma cells does not seem to correlate with response to doxorubicin-based chemotherapy (Kanzaki et al, 2001), nor is it upregulated in patients with breast cancer that were previously treated with anthracyclines versus those patients that were not treated with these drugs (Faneyte et al, 2002).…”

Section: Cellular Accumulation and Transport Of Cptsmentioning

confidence: 99%

“…Cellular Khanna et al, 2000). BCRP seems to be expressed at low levels in breast cancer cells as well as leukemic cells (Ross et al, 2000;Kanzaki et al, 2001). Recently, BCRP protein expression was found to increase in leukemia cells following infusion of topotecan and arabinoside-C in patients .…”

Section: Resistance To Cpt In the Clinical Settingmentioning

confidence: 99%

Mechanisms of resistance to topoisomerase I-targeting drugs

Rasheed¹,

Rubin²

2003

Oncogene

154

129

View full text Add to dashboard Cite

“…[2][3][4] TTV may be transmitted parenterally through transfusion of blood products, [5][6][7] by the fecal-oral route, and by pregnant women to fetuses. 8,9 TTV may also be disseminated by aerosols, since the virus is present in saliva. 8,10 A high rate of TTV infection was found in patients given multiple transfusions 11 and patients with hemophilia.…”

Section: Introductionmentioning

confidence: 99%

“…8,9 TTV may also be disseminated by aerosols, since the virus is present in saliva. 8,10 A high rate of TTV infection was found in patients given multiple transfusions 11 and patients with hemophilia. 5,12-14 TTV sequences are frequently detected in clotting factor concentrates prepared from large plasma pools.…”

Section: Introductionmentioning

confidence: 99%

TT virus contaminates first-generation recombinant factor VIII concentrates

Azzi

Santis

Morfini

et al. 2001

Blood

View full text Add to dashboard Cite

Recombinant factor VIII and factor IX concentrates, human-plasma-derived albumin, and samples from previously untreated patients with hemophilia were examined for the presence of TT virus (TTV) by using polymerase chain reaction testing. Blood samples from the patients were obtained prospectively before and every 3 to 6 months after therapy was begun. TTV was detected in 23.5% of the recombinant-product lots and 55.5% of the albumin lots tested. Only first-generation factor VIII recombinant concentrates stabilized with human albumin were positive for TTV, whereas all second-generation (human protein-free) concentrates were negative for the virus. In 59% of patients treated with either first-or second-generation recombinant factor concentrates, TTV infection developed at some point after the initial infusion. Infection with TTV in these patients before and after treatment did not appear to be clinically important. Thus, first-generation recombinant factor VIII concentrates may contain TTV and the source of the viral contamination may be human albumin. IntroductionTT virus (TTV) is a small, naked, single-stranded DNA virus of the Circoviridae family with a circular genome. It was first detected in the serum of patients with posttransfusion hepatitis of unknown cause. 1 It is not known whether TTV is pathogenic. 2-4 TTV may be transmitted parenterally through transfusion of blood products, [5][6][7] by the fecal-oral route, and by pregnant women to fetuses. 8,9 TTV may also be disseminated by aerosols, since the virus is present in saliva. 8,10 A high rate of TTV infection was found in patients given multiple transfusions 11 and patients with hemophilia. 5,12-14 TTV sequences are frequently detected in clotting factor concentrates prepared from large plasma pools. 5,15 First-generation recombinant human factor VIII concentrates stabilized with human-plasma-derived albumin (HPDA) before lyophilization (Recombinate, Baxter, Glendale, CA; and Kogenate, Bayer, Leverkusen, Germany) have been licensed for more than 10 years. They became widely used by patients with hemophilia because of their perceived safety with respect to viral infection. However, parvovirus B19 DNA was detected by polymerase chain reaction (PCR) assay in a few lots of Kogenate, 16 and seroconversion occurred in a few patients with hemophilia who were treated with this product. 17 The source of the B19 virus contamination in recombinant products was thought to be the HPDA used to stabilize the recombinant protein before lyophilization. Second-generation recombinant factor VIII and factor IX concentrates that do not contain albumin (ReFacto and Benefix, Genetics Institute, Cambridge, MA) were recently licensed for the treatment of hemophilia. A prospective study of the viral safety of these concentrates in accordance with International Society on Thrombosis and Haemostasis guidelines has not yet been conducted. To assess the safety of recombinant concentrates regarding TTV transmission, we tested several such products for TTV DNA by using PCR assays. ...

show abstract

Detection of TT virus DNA in specimens other than blood

Cited by 92 publications

References 9 publications

Current and Future Prospects of Torque Teno Virus

Current and Future Prospects of Torque Teno Virus

Mechanisms of resistance to topoisomerase I-targeting drugs

TT virus contaminates first-generation recombinant factor VIII concentrates

Contact Info

Product

Resources

About